WASHINGTON The Food and Drug Administration and the National Institutes of Health hope to accelerate the availability of medical products for patients under an initiative announced Wednesday.
The two organizations said they aimed to use translational science –– the shaping of basic scientific discoveries into treatments –– and regulatory science to more efficiently develop products and effectively evaluate product safety, efficacy and quality.
Part of the effort will involve creating a joint NIH-FDA leadership council to ensure that regulatory considerations are included in biomedical research planning and that the latest science is integrated into the regulatory review process.
“We’ve all been following the remarkable advances in biomedical sciences led by the NIH with great enthusiasm for years,” Health and Human Services secretary Kathleen Sebelius said in a statement. “However, much more can be done to speed the process from new scientific discoveries to treatments for patients.”
The organizations plan to have a public meeting in the spring to solicit input on how they can collaborate.